Quick Answer
LEXICON PHARMACEUTICALS, INC. reported Operating Income Loss of -$48.91 million for the year ending 2025.
- LEXICON PHARMACEUTICALS, INC. showed an increase of +75.2% in Operating Income Loss from 2024 to 2025.
- This data is from LEXICON PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), LEXICON PHARMACEUTICALS, INC.'s Operating Income Loss has grown by 45.6%.
- Historical annual values: Fiscal year 2025: -$48.91 million | Fiscal year 2024: -$197.12 million | Fiscal year 2023: -$171.75 million | Fiscal year 2022: -$100.76 million | Fiscal year 2021: -$87.09 million | Fiscal year 2020: -$47.80 million | Fiscal year 2019: $141.45 million | Fiscal year 2018: -$103.28 million | Fiscal year 2017: -$130.62 million | Fiscal year 2016: -$127.17 million | Fiscal year 2015: $1.47 million | Fiscal year 2014: -$100.37 million | Fiscal year 2013: -$102.37 million | Fiscal year 2012: -$108.42 million | Fiscal year 2011: -$114.10 million | Fiscal year 2010: -$95.72 million | Fiscal year 2009: -$89.96 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: